RxDoctor Payments Data

Vivian Perlman, PA

Physician Assistant · Scottsdale, AZNPI 1811045263

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 703 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,818in general payments, 2019–2025

Across 703 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$2K
  • AstraZeneca$849
  • Teva Pharmaceuticals USA, Inc.$820
  • Lilly USA, LLC$647
  • Pfizer$549
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$2722%
  • Food & beverage$12,52298%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie157$1,972
UCB, Inc.113$1,716
AstraZeneca(2 entities)26$849
Teva Pharmaceuticals USA, Inc.24$820
Lilly USA, LLC38$647
Pfizer55$549
Novartis30$499
SK Life Science, Inc.15$381
Eisai Inc.15$379
Argenx US, Inc.15$377
Novo Nordisk3$353
Amneal Pharmaceuticals LLC13$346
Neurocrine Biosciences, Inc.14$310
Biohaven Pharmaceutical Holding Company Ltd.17$233
Neurelis, Inc.11$220
Impel Pharmaceuticals Inc.9$183
Lundbeck LLC9$179
Amgen(2 entities)10$175
Biohaven Pharmaceuticals, Inc.12$158
MDD US Operations, LLC2$155
Alnylam Pharmaceuticals Inc.9$154
Harmony Biosciences LLC8$151
Sanofi5$118
Jazz Pharmaceuticals Inc.4$105
Acadia Pharmaceuticals Inc5$102
Acorda Therapeutics, Inc4$81
EMD Serono, Inc.3$77
Upsher-smith Laboratories LLC4$74
Biogen4$72
CSL Behring3$68
Octapharma USA, Inc.2$67
Bristol Myers Squibb4$67
Medtronic3$62
Otsuka America Pharmaceutical, Inc.3$61
Tonix Medicines, Inc.3$60
Merz Pharmaceuticals, LLC2$59
Genentech USA, Inc.2$57
GE HealthCare3$57
Tanabe Pharma America, Inc.3$52
Avanir Pharmaceuticals, Inc.3$52
Axsome Therapeutics, Inc.2$49
Collegium Pharmaceutical, Inc.3$44
Tersera Therapeutics LLC1$39
Arbor Pharmaceuticals, Inc.3$37
Sumitomo Pharma America, Inc.3$37
Cycle Pharmaceuticals Inc1$31
Ipsen Biopharmaceuticals, Inc1$31
Mallinckrodt Hospital Products Inc.1$30
Almatica Pharma LLC2$28
Microtransponder, Inc.1$26
Averitas Pharma Inc.1$26
Impel Pharmaceuticals LLC1$26
Xeris Pharmaceuticals, Inc.1$25
ZOLL Respicardia, Inc.1$24
Inspire Medical Systems, Inc.1$23
Viiv Healthcare Company1$23
Sandoz1$22
Nevro Corp.1$22
Kyowa Kirin, Inc.1$20
Catalyst Pharmaceuticals, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,818 in reported general payments places this provider in the 95th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$58,740
Medicare patients
248
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FycompaPerampanel13$17,362
Emgality PenGalcanezumab-Gnlm18$12,201
AdlarityDonepezil Hcl12$5,261
Lacosamide46$3,526
Levetiracetam86$3,426
Gabapentin124$1,461
Donepezil Hcl104$1,376
Memantine Hcl68$1,312
Pregabalin50$1,159
Carbidopa-LevodopaCarbidopa/Levodopa68$1,061
Propranolol Hcl39$753
Oxcarbazepine12$599
Quetiapine Fumarate18$498
Duloxetine Hcl22$453
Escitalopram Oxalate25$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$379$17,36213 claims
Upsher-smith Laboratories LLCTopiramate$74$8512 claims
Almatica Pharma LLCSertraline Hcl$28$3512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →